IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.95
+0.10 (+1.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.85
Open8.86
Bid8.57 x 800
Ask9.03 x 1100
Day's Range8.80 - 8.98
52 Week Range4.80 - 13.41
Volume1,175,375
Avg. Volume2,538,757
Market Cap1.332B
Beta3.37
PE Ratio (TTM)N/A
EPS (TTM)-1.24
Earnings DateNov 1, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble — Discovering Underlying Factors of Influence

    NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ingevity ...

  • Business Wire20 days ago

    ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Canaccord Genuity Growth Conference. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

  • ImmunoGen's Investors Play the Waiting Game
    Motley Fool20 days ago

    ImmunoGen's Investors Play the Waiting Game

    Crucial data is expected in the first half of next year.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of IMGN earnings conference call or presentation 27-Jul-18 12:00pm GMT

    Q2 2018 ImmunoGen Inc Earnings Call

  • ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
    Zacks21 days ago

    ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

    ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.

  • ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
    Zacks24 days ago

    ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

    ImmunoGen (IMGN) delivered earnings and revenue surprises of -3.45% and -34.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • ImmunoGen (IMGN) Q2 Loss Wider, Revenues Miss
    Zacks24 days ago

    ImmunoGen (IMGN) Q2 Loss Wider, Revenues Miss

    ImmunoGen posted wider-than-expected loss in the second quarter of 2018. Moreover, revenues missed estimates, significantly decreasing year over year.

  • Business Wire24 days ago

    ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results

    Mirvetuximab Soravtansine Granted Fast Track Designation by FDA

  • ACCESSWIRE24 days ago

    ImmunoGen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 27, 2018 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 27, 2018 at 8:00 AM Eastern Time. To listen ...

  • Benzinga25 days ago

    Immunogen Earnings Preview

    Immunogen (NASDAQ: IMGN ) releases its next round of earnings Friday. Here's Benzinga's essential guide to Immunogen's Q2 earnings report. Earnings and Revenue Wall Street expects an EPS loss of 29 cents ...

  • What's in Store for ImmunoGen (IMGN) This Earnings Season?
    Zacks26 days ago

    What's in Store for ImmunoGen (IMGN) This Earnings Season?

    ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.

  • Here's Why ImmunoGen Fell 15.1% in June
    Motley Foollast month

    Here's Why ImmunoGen Fell 15.1% in June

    A secondary offering dilutes investors.

  • Business Wirelast month

    ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results

    ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second quarter operating results. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

  • Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
    Motley Fool2 months ago

    Better Buy: Exelixis, Inc. vs. Immunogen, Inc.

    Which of these cancer-focused biotech stocks is the better pick right now?

  • ACCESSWIRE2 months ago

    Free Technical Research on ImmunoGen and Three More Biotech Equities

    On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).

  • Business Wire2 months ago

    ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 2,055,000 shares of ImmunoGen’s common stock at a price of $11.00 per share, before underwriting discounts. The exercise of the option brings the total shares of common stock to be sold by ImmunoGen in the offering to 15,755,000 shares. All of the shares in the offering are to be sold by ImmunoGen.

  • ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
    Zacks2 months ago

    ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

    With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

  • Business Wire2 months ago

    ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy. “We are pleased the FDA has granted Fast Track designation for mirvetuximab soravtansine,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.

  • Business Wire2 months ago

    ImmunoGen Announces Closing of Public Offering of Common Stock

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share. The gross proceeds to ImmunoGen from the offering (before deducting the underwriting discounts and offering expenses) were $150.7 million. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount.

  • Here's Why ImmunoGen Inc. Fell 9.2% Today
    Motley Fool2 months ago

    Here's Why ImmunoGen Inc. Fell 9.2% Today

    A secondary offering will dilute investors.

  • Business Wire2 months ago

    ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share, before underwriting discounts. In addition, ImmunoGen has granted the underwriters a 30-day option to purchase up to an additional 2,055,000 shares of common stock at the public offering price, less the underwriting discount. The offering was upsized from the previously announced offering size of 12,000,000 shares of common stock.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...

  • Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times?
    Simply Wall St.2 months ago

    Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times?

    Understanding ImmunoGen Inc’s (NASDAQ:IMGN) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...

  • MarketWatch2 months ago

    Immunogen shares down 4% after company's plans for secondary offering

    Shares of Immunogen Inc. fell more than 4% late Tuesday after the biotech company said it plans to offer and sell 12 million shares of its common stock in a public offering. J.P. Morgan Securities, Goldman Sachs, and Cowen and Co. are joint book-runners. Shares of Immunogen ended the regular trading session up 7.4%.

  • Business Wire2 months ago

    ImmunoGen Announces Proposed Public Offering of Common Stock

    ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.